Display options
Cite
Brzezniak C, Schmitz BA, Peterson PG, et al. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016;9(1):45-50doi: 10.1159/000443605.
Brzezniak, C., Schmitz, B. A., Peterson, P. G., Degesys, A., Oronsky, B. T., Scicinski, J. J., Caroen, S. Z., & Carter, C. A. (2016). RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case reports in oncology, 9(1), 45-50. https://doi.org/10.1159/000443605
Brzezniak, Christina, et al. "RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report." Case reports in oncology vol. 9,1 (2016): 45-50. doi: https://doi.org/10.1159/000443605
Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016. PMID: 26933418; PMCID: PMC4748757.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Case reports in oncology

Christina Brzezniak, Bruno A Schmitz, Paul G Peterson, Aiste Degesys, Bryan T Oronsky, Jan J Scicinski, Scott Z Caroen, Corey A Carter

Affiliations

  1. Walter Reed National Military Medical Center, Bethesda, Md., USA.
  2. EpicentRx, Inc., Mountain View, Calif., USA.

PMID: 26933418 PMCID: PMC4748757 DOI: 10.1159/000443605

Abstract

We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and immunologic activity, in the context of a phase II clinical trial called TRIPLE THREAT. Currently, no adequate treatment options exist for patients with EGFR mutation-positive tumors who have failed a 1st-generation tyrosine kinase inhibitor (erlotinib or gefitinib) treatment and do not develop a resistant mutation. Biopsy of a large pancreatic metastasis after RRx-001 demonstrated extensive necrosis with CD3+ and CD8+ immune cell infiltration that appears to correlate with prolonged survival despite end-stage disease. These results suggest that the mode of action of RRx-001 is related to immune stimulation in addition to epigenetic inhibition.

Keywords: Epidermal growth factor receptor; Non-small cell lung cancer; RRx-001

References

  1. Clin Cancer Res. 2006 Jul 1;12(13):3908-14 - PubMed
  2. Transl Lung Cancer Res. 2015 Feb;4(1):67-81 - PubMed
  3. Curr Genomics. 2010 Nov;11(7):513-8 - PubMed
  4. Lancet Oncol. 2015 Sep;16(9):1133-42 - PubMed
  5. Cell. 2015 Aug 27;162(5):974-86 - PubMed
  6. J Thorac Oncol. 2015 Jun;10(6):910-23 - PubMed
  7. Cancer Res. 2012 May 15;72(10):2600-8 - PubMed
  8. Oncotarget. 2015 Dec 22;6(41):43172-81 - PubMed
  9. Chemother Res Pract. 2012;2012:817297 - PubMed
  10. J Clin Oncol. 2013 Mar 10;31(8):1070-80 - PubMed
  11. Mayo Clin Proc. 2008 May;83(5):584-94 - PubMed
  12. Cell. 2015 Aug 27;162(5):961-73 - PubMed
  13. Clin Cancer Res. 2007 Sep 1;13(17):5219-25 - PubMed
  14. Immunity. 2013 Jul 25;39(1):1-10 - PubMed
  15. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18661-6 - PubMed
  16. Oncogene. 2009 Aug;28 Suppl 1:S4-13 - PubMed

Publication Types